Skip to main content

AMCP Nexus 2025 Posters Main banner

Respiratory

Respiratory

Type here to filter the list

(403) Real-World Primary Non-Adherence to Biologic Therapies in Moderate-to-Severe Asthma: A Retrospective Claims Analysis
(404) Efficacy of as-needed albuterol–budesonide versus albuterol on systemic corticosteroid exposure in participants with mild asthma: BATURA prespecified analysis
(405) Efficacy of Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis (Bronchiectasis) With vs Without Maintenance Use of Macrolides: An Analysis of the ASPEN Trial
(406) The Effect of Brensocatib vs Placebo on Symptom Burden in Patients With Non-Cystic Fibrosis Bronchiectasis (Bronchiectasis) With or Without On-Study Pulmonary Exacerbations: A Post-Hoc Analysis From the ASPEN Trial
(407) As-needed albuterol–budesonide decreases risk of severe asthma exacerbation in the first three months post-randomization compared to albuterol in patients treated for moderate-to-severe asthma: MANDALA post-hoc analysis
(408) Reduction in Asthma Exacerbations Following Initiation of Benralizumab Among Medicare Beneficiaries: Results from the ZEPHYR-5 Study
(409) Dupilumab effectiveness through 24 months in patients from the United States with CRSwNP enrolled in the global AROMA registry
(410) Baseline Characteristics of Patients on Medium-Versus High-Dose Inhaled Corticosteroids in Patients Initiating Dupilumab in a Real-World Clinical Setting: The RAPID Registry
(411) Real-world outcomes after 2 years of dupilumab therapy for severe asthma: the ProVENT study
(412) The relationship between wildfire smoke exposure and childhood asthma in California
(413) The most common comorbidities leading to a diagnosis of chronic lung allograft dysfunction (CLAD)-bronchiolitis obliterans syndrome (BOS) subsequent to lung transplant (LTx) using an open administrative claims database in the United States (US)